6 completed, 3 active not recruiting, 1 approved for marketing, 1 recruiting. 4 Phase 1, 4 Phase 2, 3 Phase 3, 1 Not applicable.
Follow ripretinib: new trials by email Literature Review of ripretinib trials Research Report on ripretinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ripretinib (QINLOCK®) According to Current SmPC Ripretinib - GIST - Gastrointestinal Stromal Tumor | Completed | iOMEDICO AG | 10 | 2024-10-17 | 2025-12-05 | |
| Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib - Gastrointestinal Stromal Tumors | Not applicable | Recruiting | First Affiliated Hospital of Chongqing Medical University | 32 | 2024-05-28 | 2024-07-18 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib Ripretinib, Sunitinib - GIST | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 54 | 2023-12-13 | 2025-12-17 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Ripretinib, binimetinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Withdrawn | Deciphera Pharmaceuticals, LLC | 2021-11-01 | 2022-01-05 | |
| A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST Ripretinib, Repaglinide - GIST - Gastrointestinal Stromal Tumor | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 13 | 2021-09-22 | 2024-09-19 |
| Ripretinib in Chinese Patients With Advanced GIST: a Real World Study Ripretinib Oral Tablet - Gastrointestinal Stromal Tumors | Unknown | Peking University | 308 | 2021-05-20 | 2023-01-25 | |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumor(GIST) | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 108 | 2020-11-25 | 2026-04-03 |
| A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) DCC-2618 - Gastrointestinal Stromal Tumors | Phase 2 | Completed | Zai Lab (Shanghai) Co., Ltd. | 39 | 2020-04-23 | 2025-03-03 |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Ripretinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 453 | 2019-02-08 | 2026-10-16 |
| Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies DCC-2618, Placebo Oral Tablet - Gastrointestinal Stromal Tumors | Phase 3 | Completed | Deciphera Pharmaceuticals, LLC | 129 | 2018-02-27 | 2022-11-21 |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis | Phase 1 | Completed | Deciphera Pharmaceuticals, LLC | 282 | 2015-11-01 | 2023-12-13 |
| Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST ripretinib - GIST - Gastrointestinal Stromal Tumor | Approved for marketing | Deciphera Pharmaceuticals, LLC | 2020-05-29 |
Gastrointestinal Stromal Tumors (13) · Carcinoma, Non-Small-Cell Lung (1) · Glioma (1) · Leukemia, Mast-Cell (1) · Mast Cell Activation Disorders (1) · Mastocytosis, Systemic (1) · Melanoma (1) · Neoplasms, Germ Cell and Embryonal (1) · Penile Neoplasms (1) · Renal Insufficiency (1) · Sarcoma (1)
Deciphera Pharmaceuticals, LLC (8) · Zai Lab (Shanghai) Co., Ltd. (2) · First Affiliated Hospital of Chongqing Medical University (1) · Peking University (1) · iOMEDICO AG (1)
Germany (6) · United States (6) · Italy (5) · Netherlands (5) · Canada (4) · China (4) · France (4) · Spain (4) · United Kingdom (4) · Australia (3) · Poland (3) · Belgium (2) · Chile (2) · Norway (2) · Singapore (2)
Jun Zhang (1) · Lin Shen, MD (1) · Zai Lab (1)
PMID 31755321, PMID 32511981, PMID 32804590, PMID 34661454, PMID 35947817, PMID 36514034, PMID 37356078, PMID 37598656, PMID 38182785, PMID 39229786, PMID 40408605